Rigrodsky & Long, P.A. Announces Investigation of SeraCare Life Sciences, Inc.’s Agreement To Be Acquired by Linden Capital...
13 Febrero 2012 - 11:33AM
Business Wire
Rigrodsky & Long, P.A. announces that it is investigating
potential claims against the board of directors of SeraCare Life
Sciences, Inc. (“SeraCare” or the “Company”) (Nasdaq: SRLS)
concerning possible breaches of fiduciary duty and other violations
of law related to the Company’s entry into an agreement to be
acquired by an affiliate of Linden Capital Partners, a
Chicago-based private equity firm, in a transaction with an
approximate value of $82 million.
Click here to learn more and to discuss your shareholder rights:
http:/www.rigrodskylong.com/investigations/SeraCare-Life-Sciences-Inc-SRLS
Under the proposed agreement, holders of outstanding shares of
common stock of SeraCare will receive $4.00 per share. The deal,
assuming all conditions are met and it is approved by shareholders
and the U.S. Securities and Exchange Commission, is expected to
close in the second quarter of 2012.
The investigation concerns whether SeraCare’s board of directors
adequately shopped the Company to obtain the best price possible
for SeraCare shareholders before entering into the agreement with
Linden Capital Partners. Indeed, according to Yahoo! Finance, at
least one analyst has set a price target of $5.00 per share for
SeraCare’s stock.
If you own the common stock of SeraCare and purchased your
shares before February 13, 2012, if you have information or would
like to learn more about these claims, or if you wish to discuss
these matters or have any questions concerning this announcement or
your rights or interests with respect to these matters, please
contact Seth D. Rigrodsky, Esquire or Scott J. Farrell, Esquire, of
Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980,
Wilmington, Delaware 19801, by telephone at (888) 969-4242, or by
e-mail to info@rigrodskylong.com.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware
and Garden City, New York, regularly litigates securities class,
derivative and direct actions, shareholder rights litigation and
corporate governance litigation, including claims for breach of
fiduciary duty and proxy violations in the Delaware Court of
Chancery and in state and federal courts throughout the United
States.
Attorney advertising. Prior results do not guarantee a similar
outcome.
Seracare Life Sciences (NASDAQ:SRLS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Seracare Life Sciences (NASDAQ:SRLS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
